liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Johns Hopkins University.
Karo Bio.
University of Colorado.
Linköping University, Department of Medical and Health Sciences, Internal Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
Show others and affiliations
2010 (English)In: NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, Vol. 362, no 10, 906-916 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided. METHODS We performed a randomized, placebo-controlled, double-blind, multicenter trial to assess the safety and efficacy of the thyromimetic compound eprotirome (KB2115) in lowering the level of serum LDL cholesterol in patients with hypercholesterolemia who were already receiving simvastatin or atorvastatin. In addition to statin treatment, patients received either eprotirome (at a dose of 25, 50, or 100 mu g per day) or placebo. Secondary outcomes were changes in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Patients were monitored for potential adverse thyromimetic effects on the heart, bone, and pituitary. RESULTS The addition of placebo or eprotirome at a dose of 25, 50, or 100 mu g daily to statin treatment for 12 weeks reduced the mean level of serum LDL cholesterol from 141 mg per deciliter (3.6 mmol per liter) to 127, 113, 99, and 94 mg per deciliter (3.3, 2.9, 2.6, and 2.4 mmol per liter), respectively, (mean reduction from baseline, 7%, 22%, 28%, and 32%). Similar reductions were seen in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Eprotirome therapy was not associated with adverse effects on the heart or bone. No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotirome. CONCLUSIONS In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins.

Place, publisher, year, edition, pages
2010. Vol. 362, no 10, 906-916 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-54499DOI: 10.1056/NEJMoa0905633ISI: 000275365900011PubMedID: 20220185OAI: diva2:304602
Available from: 2010-03-19 Created: 2010-03-19 Last updated: 2014-10-03

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedLink to article

Search in DiVA

By author/editor
Olsson, Anders
By organisation
Internal MedicineFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 22 hits
ReferencesLink to record
Permanent link

Direct link